The efficacy of hepatitis B treatments in achieving HBsAg seroclearance: A systematic review and meta‐analysis
- 14 March 2020
- journal article
- review article
- Published by Wiley in Journal of Viral Hepatitis
- Vol. 27 (7), 650-662
- https://doi.org/10.1111/jvh.13283
Abstract
Current therapies for Chronic Hepatitis B (CHB) include nucleos(t)ide analogues (NA) and interferon (IFN) but their relative efficacy as monotherapy or in combination has not been examined systematically for HBsAg loss (functional cure). Hence we systematically reviewed the evidence for HBsAg loss in CHB patients treated with IFN, NA or the combination.We searched PubMed, EMBASE and abstracts from EASL, APASL and AASLD forrandomized controlled trials of CHB patients, comparing NA, IFN or the combination.The Cochrane Risk of Bias tool v2.0 and GRADE method were used. Analyses were stratified by NA genetic barrier, cirrhosis, type of combination therapy, HBeAg, treatment naivety, interferon dosage/duration and outcome duration. Sensitivity analysis was performed for selected strata and HBsAg loss was measured at the end‐of‐study(EOS), end‐of‐treatment(EOT) or end‐of‐followup(EOF). Effects were reported as risk differences (RD) with 95% confidence intervals (CI) using a random‐effects model. Forty five studies were included, all with low risk of bias. For HBsAg loss at EOS, when comparing combination versus IFN, RD=1%, 95%CI‐1%,2%; combination versus NA, RD=5%, 95%CI 3%,7%; IFN versus NA, RD=3%, 95%CI 2%,5%. Subgroup analysis showed a significant effect of standard IFN dose versus non‐standard; IFN duration≥48weeks versus 2years of followup. Similar findings were seen in HBsAgseroconversion but only 3 studies reported HBsAgseroreversion. In conclusion, IFN monotherapy/combination had a small but significant increase in HBsAg loss over NA, associated with standard dose of IFN and ≥48weeks of therapy, although this effect faded over time.Keywords
Funding Information
- National Medical Research Council (NMRC/CIRG/1351/2013, NMRC/CIRG/1479/2017, NMRC/CSA‐SI/0016/2017, NMRC/TCR/014‐NUHS/2015)
This publication has 44 references indexed in Scilit:
- Sustained Responses and Loss of HBsAg in HBeAg-Negative Patients With Chronic Hepatitis B Who Stop Long-Term Treatment With AdefovirGastroenterology, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- A randomized controlled trial of pegylated interferon-α2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis BAntiviral Therapy, 2009
- Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infectionThe Esophagus, 2008
- Pegylated Interferon Alfa-2b Monotherapy and Pegylated Interferon Alfa-2b plus Lamivudine Combination Therapy for Patients with Hepatitis B Virus E Antigen-Negative Chronic Hepatitis BAntimicrobial Agents and Chemotherapy, 2007
- Sequential treatment with lamivudine and interferon- monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutationsJournal of Antimicrobial Chemotherapy, 2006
- Peginterferon Alfa-2a, Lamivudine, and the Combination for HBeAg-Positive Chronic Hepatitis BNew England Journal of Medicine, 2005
- Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis BNew England Journal of Medicine, 2004
- Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonrespondersJournal of Hepatology, 2003
- Comparison of 12-Month Courses of Interferon- -2b-Lamivudine Combination Therapy and Interferon- -2b Monotherapy among Patients with Untreated Chronic Hepatitis BClinical Infectious Diseases, 2003